0001104659-23-108892 8-K 13 20231010 8.01 9.01 20231013 20231012 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 231323638 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2328385d1_8k.htm FORM 8-K
0001477845 false 0001477845 2023-10-10 2023-10-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 10, 2023

 

 

 

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 
     
Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

 

1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

(Address of Principal Executive Offices, and Zip Code)

 

(610) 727-3913

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

Item 8.01 Other Events.

 

On October 12, 2023, the Company issued a press release announcing the positive interim independent analysis for statistical power in its Alzheimer’s study. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
Number

 

Description

99.1   Press Release, dated October 12, 2023.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
     
Date: October 12, 2023 By: /s/ Henry Hagopian, III 
    Name: Henry Hagopian, III
    Title: Chief Financial Officer

 

 

 

EX-99.1 2 tm2328385d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

ANNOVIS BIO ANNOUNCES POSITIVE interim INDEPENDENT analysis For STATISTICAL POWER IN its Alzheimer’s study

 

October 12, 2023

 

Pre-specified, blinded interim analysis for sample size re-estimation indicates that the ongoing Phase 2/3 study in Alzheimer’s Disease (AD) is sufficiently powered to continue as planned without any additional patients.

 

BERWYN, Pa., October 12, 2023  /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the independent statistical group concluded that its Phase 2/3 AD study was sufficiently powered to continue as originally planned without the addition of patients. This phase 2/3 AD study is designed to enroll a total of 320 mild to moderate AD patients, who are randomly assigned to receive 7.5, 15, 30 mg of buntanetap or placebo once per day. The trial’s co-primary endpoints are the change from baseline to the end of treatment of Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog11) and Alzheimer’s Disease Cooperative Study Clinician’s Global Impression of Change (ADCS-CGIC), which assess cognition and activities of daily living.

 

The Company has received the results of the pre-planned interim analysis conducted by an independent data analytics provider. The interim analysis was based on 107 patients at 6 weeks from all cohorts collectively and showed that the AD trial should continue as planned with the same trial size to maintain the statistical power for both co-primary endpoints.

 

The Company remains blinded to the Phase 3 trial and does not have safety or efficacy data from the trial. A separate safety interim analysis is in process and we expect that interim analysis to be released in two weeks.

 

Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented: “Although we remain blinded to the data, results from this interim analysis supports our original statistical powering for enrolling 320 patients into the Phase 2/3 Alzheimer’s study. Therefore, sample size re-estimation for the study is not necessary, which in our view, may signal an emerging positive treatment effect in patients receiving buntanetap versus those receiving placebo after just 6 weeks of treatment. While the interim analysis does not mean that the trial will necessarily be successful, it does mean that the trial is powered for potential success.”

 

Update and projections of our ongoing activities:

 

Alzheimer’s disease

 

-to date, 230 patients have been enrolled and 62 have finished the study,

 

-safety interim analysis, conducted by the DSMB on October 18, will be released the week of October 23,

 

-full enrollment anticipated in November,

 

-completion of treatment expected in February 2024,

 

-phase 2/3 data expected in March 2024.

 

 

 

Parkinson’s disease

 

-to date, 305 patients have finished the study,

 

-completion of study expected by the end of November,

 

-phase 3 data expected in January 2024.

 

In addition to the ongoing clinical studies, we are also excited about the novel crystal form of buntanetap - ANVS402. We expect to discuss with the FDA the transition buntanetap to ANVS402 and the development of the new form. The bridge studies are expected to be completed in Q1 2024.

 

As we move forward with our advanced, clinical-stage AD and PD programs, we hope to demonstrate buntanetap’s unique ability to inhibit the accumulation of pro-inflammatory, neurotoxic proteins and potential to address unmet medical need across a number of neurodegenerative conditions and diseases.

 

About Buntanetap

 

Buntanetap (previously known as ANVS401 or Posiphen) is an investigational, oral translational inhibitor of neurotoxic aggregating proteins (TINAPs), which mode of action is thought to lead to a lower level of neurotoxic proteins and consequently less toxicity in the brain. In a Phase 2a clinical trial in AD and PD patients, buntanetap was shown to be generally well-tolerated , and its pharmacokinetics were found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were also met, as treatment with buntanetap resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients. Presently buntanetap is being studied in a Phase 3 early PD study and in a Phase 2/3 study in AD patients.

 

About Annovis Bio, Inc.

 

Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and other chronic neurodegenerative diseases. We believe that we are the only company developing a drug for AD and PD that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study buntanetap showed improvements in cognition and memory in AD as well as body and brain function in PD patients.

 

For more information on Annovis Bio, please visit the Company's website www.annovisbio.com and follow us on LinkedIn and Twitter.

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to all information other than historical matters, such as expectations or forecasts of future events. Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations, strategies, prospects and other aspects of the business of Annovis Bio are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These risks and uncertainties include but are not limited to delays in clinical trials and in reporting of the data. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in Annovis Bio's Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made.  Although it may voluntarily do so, from time to time, Annovis Bio undertakes no commitment to update or revise the forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, except as required under applicable law.

 

Media Contact:
Maria Maccecchini, PhD

maccecchini@annovisbio.com

 

 

EX-101.SCH 3 anvs-20231010.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 anvs-20231010_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 anvs-20231010_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Oct. 10, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 10, 2023
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code 610
Local Phone Number 727-3913
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 7 tm2328385d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2023-10-10 2023-10-10 iso4217:USD shares iso4217:USD shares 0001477845 false 8-K 2023-10-10 ANNOVIS BIO, INC. DE 001-39202 26-2540421 1055 Westlakes Drive Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /*<3%<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #RG$Q7TA F8>T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVE ,'1[6?&D(+B@> O)[&ZP24,RTN[;F\;=+J(/X#$S?[[Y M!J;30>HQXG,< T:RF&YF-_@D==BP(U&0 $D?T:E4YX3/S?T8G:+\C <(2G^H M T+;-+?@D)11I& !5F$ELKXS6NJ(BL9XQAN]XL-G' K,:, !'7I*P&L.K%\F MAM,\=' %+##"Z-)W 97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ M\IQ,5RN@^1&(! Q!$ !@ !X;"]W;W)KV4\JWWW&@ M">O""6_:).0\_'+.R>-C^ENE7\V&DUB:@;>Q-KUI-DVXX0DS#95R"9^L ME$Z8A5.];II4:PW[*UGS.[?=TIN&L6:A$(N'2""6)YJN!-Z(WMT'7!>1W M/ N^-4?'Q#W*4JE7=S*)!I[OB'C,0^LD&/Q[XV,>QTX)./XYB'K%=[K X^,/ M]8?\X>%AELSPL8I?1&0W ^_*(Q%?L2RV3VK[.S\\4,?IA2HV^5^RW=_;\3T2 M9L:JY! ,!(F0^__L_9"(HX!V<"(@. 0$.??^BW+*.V;9L*_5EFAW-ZBY@_Q1 M\VB $])596XU?"H@S@['ZHWK?M."E+O0# ]AM_NPX$388V@;A/H7)/"#UG_# MFT!08 0%1I#KM3 ,\M=H::R&0OU=1;17:%5519Z!KUNWL,\LC6Z3F0HR@",S07'P?D*]Q''F4U&2Y)_4Z' MO'!C8_;*#;G3L)QBK*7W4]2Z<=;%5E6RXI+S3$ U6KZ/ 9;F3W'[_@PX=F=0 MZH7:RDHX7.Z6Z^U.8F3EBD!Q2_],5G3A3*LW(5RP/%??VK"B$G MLXV2V'I5(](+>K!@46S]I.6B0'$O?]'"6BXA,4F2R8/UFDHJ7*ANVJ#E@D!Q M_YZK6(3""KDFWZ"]M6!Q)0^N4L<3E M @%OT3//+$-+#X?W:#X4PE\'X^KA: M5=>O1J^6K'3] +?H_Y%-C,F K!80EZT%/!KS<5]>" N3F5H1&OR\_(7,>9A! MOU6.'#5*KC]A)IA;%;Y>D)1I\L;BC),?_88;1T@*SVLV3*/&W=#?#Y2BG[<>)V_L4/-\-_ 5!+ P04 " #R MG$Q7GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67=A['-HN6/O.-%Q[I#)6,>=56R=M8SDK6W!2 M,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B M6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG- M@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3T MXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(? M]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I M^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE< MA!OZ%>Y7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=> MBD[E\ZI[J,NXZBQ_AOMHD\%G'!QR>(W?#$T

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports anvs-20231010.xsd anvs-20231010_lab.xml anvs-20231010_pre.xml tm2328385d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2328385d1_8k.htm": { "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20231010", "dts": { "schema": { "local": [ "anvs-20231010.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "anvs-20231010_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20231010_pre.xml" ] }, "inline": { "local": [ "tm2328385d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://annovisbio.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-10-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2328385d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-10-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2328385d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-108892-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-108892-xbrl.zip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end